ChronoScale Corporation Common Stock (NASDAQ:CHRN) Shares Down 6.1% – Should You Sell?

ChronoScale Corporation Common Stock (NASDAQ:CHRN)’s stock price fell 6.1% during trading on Wednesday . The stock traded as low as $19.78 and last traded at $19.78. 40,809 shares traded hands during trading, a decline of 83% from the average session volume of 240,936 shares. The stock had previously closed at $21.06.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a research report on Monday, August 24th. One investment analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Reduce” and a consensus target price of $6.00.

ChronoScale Corporation Common Stock Stock Performance

The stock’s 50-day moving average price is $21.37 and its 200-day moving average price is $16.64. The company has a current ratio of 0.51, a quick ratio of 0.51 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $2.70 billion, a P/E ratio of -3.45 and a beta of 0.98.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last issued its earnings results on Wednesday, August 19th. The company reported ($0.12) EPS for the quarter. The company had revenue of $18.40 million during the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. As a group, equities analysts expect that ChronoScale Corporation Common Stock will post -0.1 EPS for the current year.

Hedge Funds Weigh In On ChronoScale Corporation Common Stock

Several hedge funds have recently bought and sold shares of the business. Shay Capital LLC acquired a new position in shares of ChronoScale Corporation Common Stock during the third quarter worth approximately $67,000. Virtu Financial LLC acquired a new position in ChronoScale Corporation Common Stock in the third quarter worth about $57,000. Citadel Advisors LLC bought a new stake in ChronoScale Corporation Common Stock in the third quarter valued at $198,000. Geode Capital Management LLC grew its stake in ChronoScale Corporation Common Stock by 68.9% during the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after buying an additional 10,281 shares during the last quarter. Finally, Roble Belko & Company Inc boosted its holdings in shares of ChronoScale Corporation Common Stock by 104.5% in the 1st quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock worth $25,000 after acquiring an additional 1,195 shares in the last quarter. 6.42% of the stock is owned by institutional investors and hedge funds.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.